Cardinal Health has released a new, interactive Biosimilars Interchangeability State Laws resource. Cardinal and regulatory advisers developed this state-by-state resource to help you navigate your state’s specific guidelines and support patients with biosimilar adoption. As a reminder, the FDA approved the first interchangeable biosimilar insulin product on July 28. Semglee (insulin glargine-yfgn) is both biosimilar to and interchangeable with its reference product Lantus (insulin glargine).
NCPA
